In the last trading session, 1.23 million shares of the Plus Therapeutics Inc. (NASDAQ:PSTV) were traded, and its beta was 0.37. Most recently the company’s share price was $1.97, and it changed around $0.09 or 4.79% from the last close, which brings the market valuation of the company to $28.80M. PSTV currently trades at a discount to its 52-week high of $5.42, offering almost -175.13% off that amount. The share price’s 52-week low was $1.75, which indicates that the current value has risen by an impressive 11.17% since then. We note from Plus Therapeutics Inc.’s average daily trading volume that its 10-day average is 0.62 million shares, with the 3-month average coming to 1.35 million.
Plus Therapeutics Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended PSTV as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Plus Therapeutics Inc. is expected to report earnings per share of -$0.24 for the current quarter.
Plus Therapeutics Inc. (NASDAQ:PSTV) trade information
Instantly PSTV has showed a green trend with a performance of 4.79% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.9700 on Friday, 09/17/21 decreased the stock’s daily price by 0.0%. The company’s shares are currently down -2.48% year-to-date, but still up 3.68% over the last five days. On the other hand, Plus Therapeutics Inc. (NASDAQ:PSTV) is -7.51% up in the 30-day period. We can see from the shorts that 0.97 million shares have been sold at a short interest cover period of 0.46 day(s).
The consensus price target as assigned by Wall Street analysts is $6.50, which translates to bulls needing to increase their stock price by 69.69% from its current value. Analyst projections state that PSTV is forecast to be at a low of $6.00 and a high of $7.00. In order for the stock price to hit the forecast high, the stock would need to plunge -255.33% from its current level, while the stock would need to crash -204.57% from its current level to reach the projected low.
Plus Therapeutics Inc. (PSTV) estimates and forecasts
Plus Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -25.66 percent over the past six months and at a 47.31% annual growth rate that is well above the industry average of 18.10%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain 38.50% in revenue this quarter, and will report an increase of 62.70% in the next quarter.
Plus Therapeutics Inc.’s next quarterly earnings report is expected to be released around October 20 and October 25.
Plus Therapeutics Inc. (NASDAQ:PSTV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.33% of Plus Therapeutics Inc. shares, and 2.25% of them are in the hands of institutional investors. The stock currently has a share float of 2.28%. Plus Therapeutics Inc. stock is held by 25 institutions, with Blackrock Inc. being the largest institutional investor. By Mar 30, 2021, it held 0.57% of the shares, which is about 0.12 million shares worth $0.29 million.
Vanguard Group, Inc. (The), with 0.37% or 77086.0 shares worth $0.19 million as of Mar 30, 2021, holds the second largest percentage of outstanding shares.
Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund were the top two Mutual Funds as of Mar 30, 2021. The former held 77086.0 shares worth $0.19 million, making up 0.37% of all outstanding shares. On the other hand, Fidelity Extended Market Index Fund held roughly 6336.0 shares worth around $15206.0, which represents about 0.03% of the total shares outstanding.